Table 1.
Integrin expression by human glioma cell explants*
| ανβ3 |
ανβ5 |
VLAβ1 |
VLA5 |
|||||
|---|---|---|---|---|---|---|---|---|
| Cell explant | % Positive (MFI) | % Positive (MFI) | % Positive (MFI) | % Positive (MFI) | ||||
| 13-06-MG | 28.2 | (4.1) | 75.7 | (6.2) | 90.4 | (24.1) | 46.3 | (4.8) |
| 10-08-MG | 14.6 | (4.2) | 72.2 | (6.2) | 89.2 | (15.6) | 36.7 | (4.3) |
| 04-11-MG | 20.8 | (4.5) | 70.9 | (5.9) | 81.2 | (14.2) | 52.4 | (4.9) |
| 14-07-MG | 19.6 |
(4.5) |
71.8 |
(6.6) |
87.1 |
(17.4) |
31.5 |
(4.8) |
| Mean % + & MFI | 20.8 | (4.3) | 72.7 | (6.2) | 87.0 | (17.8) | 41.7 | (4.7) |
| Cell line | ||||||||
| U-373MG** | 73.0 | (5.5) | 68.7 | (4.6) | 98.7 | (13.4) | 25.3 | (3.0) |
| U-251MG*** | 0.9 | (4.0) | 45.9 | (4.3) | 97.9 | (10.5) | 3.4 | (3.6) |
*
Flow cytometry was used to determine the percentage of positive cells and the relative antigen density, which was expressed as the mean fluorescence intensity (MFI) of the integrin.
**
The U-373MG glioma cell line was used as a positive control for ανβ3 (Chatterjee et al, J. Neurooncol. 46:135-144, 2000).
***
The U-251MG glioma cell line was used as a negative control for ανβ3 (Chatterjee et al, ibid).